covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | September 23, 2020 | News story | Research and Development COVID-19, coronavirus 

The coronavirus news this week largely focuses on clinical trial results, with Pfizer saying that participants in a late-stage trial for its COVID-19 vaccine candidate have shown mild to moderate side effects, while Roche says that its Actermra/Roactemra drugs reduce the likelihood that coronavirus patients with virus-related pneumonia will need to be put on a ventilator.

In other news, a new study that alleges COVID-19 was created in a Chinese lab was published by two non-profits that are linked to President Trump’s former chief strategist Steve Bannon.

1.Pfizer’s coronavirus vaccine shows moderate side-effects in clinical studyPublished 16/09/20

Pfizer has said that participants in a late-stage trial for its COVID-19 vaccine candidate have shown mild to moderate side effects.

2. Study that alleges COVID-19 was made in a Chinese lab originated from non-profits linked to ex-Trump advisor Steve BannonPublished 16/09/20

A new study that alleges COVID-19 was created in a Chinese lab was published by two non-profits that are linked to President Trump’s former chief strategist Steve Bannon, it has emerged.

3. India signs deal for 100m doses of Russia’s Sputnik V COVID-19 vaccinePublished 16/09/20

Russia has signed a deal with an Indian pharma firm to test and deliver 100 million doses of its controversial Sputnik V vaccine for COVID-19 to the nation’s citizens as it sees its death toll surge to overtake Brazil as the second-worst hit country on Earth after the US.

4. Oxford University says participant illness that halted its COVID-19 trial may not be linked to the vaccinePublished 17/09/20

The illness of one of the participants in the Oxford-AstraZeneca COVID-19 vaccine trial may not have been caused by the treatment itself, according to newly revealed information.

5. Roche says its rheumatoid arthritis drug reduces the need for ventilators in coronavirus patientsPublished 18/09/20

Roche says that its Actermra/Roactemra drugs reduce the likelihood that coronavirus patients with virus-related pneumonia will need to be put on a ventilator.

Conor Kavanagh

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …

moderna_norwood_plant

Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content